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The Use of Nano Polymeric Self-Assemblies Based on Novel Amphiphilic 
Polymers for Oral Hydrophobic Drug Delivery 
 
1. Introduction 
 Polymeric self-assemblies have been widely studied for their potential as hydrophobic drug 
solubilising agents since they were first reported in 1984 [1]. They are commonly formed from 
amphiphilic polymers where these polymers consist of hydrophilic and hydrophobic segments 
within the same macromolecules. In aqueous environment, polymeric self-assemblies with core–
shell structures are formed upon the aggregation of hydrophobic moieties. The most common type 
of self-assemblies are spherical polymeric micelles [2] with other less common assemblies such as 
nanoparticles [3], disc-like structures [4], filamentous structures [5] or vesicles[6] have also been 
reported. Hydrophobic drugs can physically be encapsulated inside the lipophilic core of these self-
assemblies mainly attributed to hydrophobic interaction [6,7]. Today, polymeric self-assemblies are 
widely developed for intravenous administration in particular for cancer therapy [2,7] but their use 
in other routes of administration such as oral delivery is much less reported [7,8]. Recently a few 
research groups have investigated the use of polymeric micelles in the oral delivery of hydrophobic 
drugs such as risperidone [9], cyclosporine [10], paclitaxel [11], lodamin [12], griseofulvin [13] and 
doxorubicin [2]. It is thought that apart from the solubilisation effect and depending on the type of 
the amphiphilic polymers, they exhibited other unique properties such as mucoadhesive properties 
[14], protection against enzymatic degradation [15], inhibition of P-glycoprotein pump [16] or 
enhancement of cellular uptake by CaCo2 cells [17], which showed great potential in oral delivery.   
 The most common amphiphilic polymer architecture investigated in oral delivery is block 
copolymers [9], however recently diverse structures such as hydrophobically modified polymers 
[15,18] and dendrimers [19] have also been reported. The hydrophobic pendant groups in 
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hydrophobically modified polymers are traditionally composed of hydrocarbon chains of different 
lengths such as alkyl, acyl [20] or sterol-like moieties [21]. Unlike block copolymer, investigation 
into the effect of these hydrophobic pendant groups on drug solubilisation is seldom investigated. 
Based on the observations reported for block copolymers, it has been well established that apart 
from the drug physicochemical properties, the degree of compatibility or interaction between the 
hydrophobic core-forming polymer and the drug can influence the colloidal stability, encapsulation 
efficiency and drug release kinetics [2].  Rekatas and colleagues reported that block copolymers 
consisting of polystyrene oxide as the core-forming polymer were able to encapsulate a higher level 
of drugs with aromatic rings than aliphatic hydrophobic polymers [22]. 
However, despite most hydrophobic drugs consist of aromatic or cyclic ring systems, to our 
best knowledge, the attachment of aromatic groups to a pre-formed water soluble polymer 
backbone, where the aromatic groups serve as the only hydrophobic moiety have not yet been 
explored for oral hydrophobic drug delivery. Here we investigate the ability of novel 
poly(allylamine) (PAA) modified  with different types and levels of aromatic pendant groups 
(Fluorenylmethoxy carbonyl (fmoc) and dimethylamino-1-naphthalenesulfonyl (dansyl) on the 
enhancement of hydrophobic drug solubility and oral absorption (Fig 1). They will be compared to 
cholesteryl grafted PAA (Ch), that was recently demonstrated as a potential cancer therapy for 
parenteral delivery [23] (Fig 1). Cross-linked PAA has been used clinically as an oral phosphate 
binder [24] while thiolated PAAs had been investigated as intestinal permeation enhancer [25] but 
amphiphilic PAA for drug delivery application is seldom reported. Three hydrophobic drugs 
containing aromatic or cyclic ring structures, propofol (Mw= 178 gmol
-1
, logP =4.16), prednisolone 
(Mw= 360 gmol
-1
, logP= 1.8) and griseofulvin (Mw=353 gmol
-1
, logP= 2.2) will be used as model 
drugs (Fig1). Their physicochemical properties, in vitro drug release, formulation stability and in 
vitro biocompatibility will be elucidated and finally their potential in oral delivery of griseofulvin 




2. Materials and methods 
15kDa poly(allylamine) hydrochloride (PAA), propofol, prednisolone, griseofulvin, etoposide, 
orthophosphoric acid, potassium dihydrogen phosphate, octane sulfonic acid, anhydrous sodium 
acetate, Minimal Essential Media (MEM), Dulbecco’s minimal essential media (DMEM), L-
Glutamine, Non essential amino acids, Glycerol, Triton-X , 3-[4,5-dimethyl thiazol-2-yl]-
2,5diphenyl tetrazolium bromide (MTT) and L-Glycine were purchased from Sigma-Aldrich Co. 
(UK). HPLC grade solvents, phosphate buffered saline (PBS), Foetal Bovine Serum (FBS), Trypsin 
EDTA and penicillin streptomycin were purchased from Fisher Scientific (UK). 0.45μm GDX 
PVDF syringe filters were from Whatman (UK).  
2.1 Polymer synthesis and characterisation 
PAA was reacted with cholesteryl chloroformate, 9 fluorenylmethoxy carbonyl chloride (fmoc-
chloride) and 5-Dimethylamino-1-naphthalenesulfonyl chloride (dansyl chloride) based on molar 
feeds of 20:1 and 10:1 (PAA monomer: hydrophobic group) to yield PAA modified with 
cholesteryl, fmoc and dansyl pendant groups (Ch, Fmoc and Dansyl respectively). The novel 
amphiphilic polymers were characterised by elemental analysis and 
1
H NMR and the results 
confirmed 4.7, 4.3 and 7.1% mole modification for Ch5, Fmoc5 and Dansyl5 respectively and 9.3% 
for both Fmoc10 and Dansyl10 [18].The numerals of the polymer abbreviation indicate the % 
expected mole modification based on the initial molar feeds. 10% mole modification of Ch resulted 
in an insoluble product and hence no further work was pursued with this polymer. 
2.2 Drug Loading  
Polymer in deionised water (1, 3 and 6mgmL
-1
) was probe sonicated for 10 min. The hydrophobic 
drug was added at 1:1, 5:1 and 10:1 initial drug: polymer weight ratios and the drug-polymer 
solutions were probe sonicated for a further 10 min. All drugs were added in powder form except 
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for propofol which was an oily viscous liquid. After cooling to room temperature, the solutions 
were filtered using 0.45 µm syringe filters (with pre-filters) to remove any excess drugs.  
 
2.2.1 Quantification of propofol  
Propofol in the self-assemblies was determined using high performance liquid chromatography 
(HPLC) (Shimadzu prominence UFLC, UK), as previously reported by Qu and colleagues [26]. A 
RP Zorbax ODS 250 mm x 46 mm x 5 µm HPLC column (Hichrom, UK) was used with the flow 
rate of 1 mLmin
-1
 (80:20 v/v methanol:water) in an isocratic mode. The samples were diluted with 
mobile phase and 20 µL was injected onto the column. The resultant peak at 7 min was analysed at 
229 nm (Shimadzu prominence UFLC, UK). Propofol in the samples were determined using a 
calibration graph constructed from propofol standards dissolved in methanol (4 µgmL





= 0.999.  
2.2.2 Quantification of prednisolone 
HPLC consisted of a RP Phenomenex C18 150 mm x 4.6 mm x 3.5 µm column with the mobile 
phase (36:64 (v/v) acetonitrile:water)  and a flow rate of 1 mLmin
-1
. The prednisolone peak eluted 
at 3min and detected at max 243nm. Standards were prepared in the mobile phase (6 µgmL
-1
 – 25 
µgmL
-1
) and a calibration was constructed, (R
2 
= 0.999) to determine the concentration of 
prednisolone in the formulation. 
2.2.3 Quantification of griseofulvin 
This method was an adaptation of Trimaille’s method [27]. In brief the samples were passed 
through a RP Phenomenex C18 250 mm x 46 mm x 5 µm HPLC column and the peak (9.5min) was 
detected at max 293 nm . The mobile phase (45:55 v/v) acetonitrile:45 mM potassium dihydrogen 
phosphate buffer (adjusted to pH3 with orthophosphoric acid) was at 1 mLmin
-1
 and 20 µL of 
sample diluted with the mobile phase was injected onto the column. The concentration of 
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griseofulvin in the samples was determined from a calibration graph of griseofulvin standards (0.6 
µgmL
-1
 – 10 µgmL-1), R2 = 0.999. 
 
For all formulations, the % drug loading capacity (LC) and % drug encapsulation efficiency (EE) 
was calculated based on the equations below: 
% LC = drug determined by HPLC/ polymer concentration x 100%        (1) 
% EE = drug determined by HPLC/ original drug concentration X100% (2) 
2.3 Sizing of Nano-aggregates 
Hydrodynamic sizes of the drug formulations (in deionised water) were determined using a photon 
correlation spectroscopy (PCS) (Zetasizer Nano-ZS, Malvern Instruments, UK). All measurements 
were conducted in triplicate at 25 °C and an average value was determined.  
2.4 Transmission Electron Microscopy (TEM) 
 Formvar/carbon-coated 200 mesh nickel grids were glow discharged and one drop of the 
formulations prepared as described above, was dried onto the hydrophilic support film.  1 % 
aqueous methylamine vanadate (20 µL) (Nanovan;  Nanoprobes , Stony Brook, NY, USA) stain 
solution was applied and the mixture dried down immediately with filter paper to remove excess 
liquid. The dried samples were imaged with a LEO 912 energy filtering transmission electron 
microscope at 120 kV. Contrast enhanced, zero-loss energy filtered digital images were recorded 
with a 14 bit /2 K Proscan CCD camera. 
2.5 In vitro drug release 
The method used was an adaptation of Lee and colleagues [28]. The optimum  Ch5 and Dansyl 10 
formulations with the initial polymer: drug weight loading of 1:10 ,and polymer concentration at 
6mgmL
-1
 were prepared as described in section 2.2. The formulation (2 mL) was pipetted in a 
dialysis tubing (MW cut off = 12-14 kDa) and dialysed against PBS in sink condition (200 mL, 0.2 
M) at 37 ºC with stirring. At various time points 1 mL of PBS was extracted and replaced with 1 
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mL of fresh PBS. The amount of drug in the collected PBS was determined using HPLC as 
described above. 
2.6 Stability testing of Formulations 
The formulations were prepared as previously described (section 2.2) in either solution or freeze 
dried forms and were stored in air tight desiccators (55% humidity) at room temperature and in the 
dark. At specific time points, the drug content in the filtered, freeze-dried and reconstituted 
formulations as well as the formulations in solutions were analysed using HPLC as described 
above. 
2.7 Biological characterisation 
2.7.1 Haemolysis Assay 
Fresh bovine blood (approximately 50 mL) was washed with copious amount of phosphate buffered 
saline (PBS buffer) (0.1 M) and centrifuged (2500 rpm) for 10 min at 4 ºC. The supernatant was 
discarded. This process was repeated until the supernatant was clear. The red blood cell (RBC) was 
weighed and fresh PBS was added to achieve 3 % (w/v). The red blood cell suspended in PBS (80 
µL) was then pipetted into a 96 well round bottom plate. 10mgmL
-1
 polymer stock solution was 
prepared in water adjusted to pH7.4. A range of polymer concentrations (0.05-1 mgmL
-1
) were 
prepared from the polymer stock solution using PBS as the diluents and added (80 µL) to RBC. The 
plates (160uL/well) were incubated at 37 ºC for 4 h before centrifuged at 2500 rpm for 10 min at 4 
ºC. The supernatant (100 µL) was transferred to a flat bottomed 96 well plate and the absorbance 
was read at 570 nm (microplate reader, Ascend Lab-Systems, UK). PBS and Triton X (80 µL each) 
were used as the negative and positive controls respectively. The results expressed as percentage 
haemolysis assuming Triton X gave 100% haemolysis and PBS gave 0% haemolysis. The RBC 
pellets were viewed under the light microscope (Leica DM3000B, Leica UK) and images were 
captured. 
2.7.2 Cytotoxicity Assay  
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Caco-2 cells (EDACC, passage number 10) were cultured in minimum essential medium (MEM) 
containing 10 % foetal bovine serum (FBS), 1 % L- glutamine and 1 % non essential amino acids 




) were prepared from 
stock solution (0.5 mgmL
-1
 in 1:20 water: media). Caco-2 cells (200µL, 10000 cells/well) in 
exponential growth were seeded in a 96-well plate and incubated for 24 h at 37 ºC with 5 % CO2. 
The media was then removed via aspiration and replaced with the aforementioned polymer 
solutions (200L). After 24h, the polymer solutions were removed and replaced with fresh media 
and incubated for a further 24h. The media was then replaced with fresh media and 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT) (50 µL, 5 mgmL
-1
) was added to the wells 
and incubated in the dark for 4 h. MTT solution was removed and the purple formazan complexes 
formed, were dissolved in DMSO (200 μL) and L-glycine buffer (20L) (3.75 g glycine and 2.93 g 
NaCl in 500 mL water and adjusted to pH 10.5).The absorbance was read at 570 nm using a 
microplate reader (Ascend Lab-Systems, UK) and the percentage cell viability was calculated 
relative to the positive (Triton X,1:5 v/v PBS) and negative (media) controls. 
2.8 In vivo oral absorption study 
2.8.1 Formulation preparation 
Ch5 and Dansyl10 (6mgmL
-1
), griseofulvin formulations were prepared as described in section 2.2 
using polymer: drug weight ratio of 1:10. Based on HPLC quantification, Dansyl formulation was 





) in distilled water was prepared in a similar manner as 
described above in the absence of polymer. Polymer solutions were used as controls. 
2.8.2 Intragastric administration and evaluation of griseofulvin absorption 
18 male Sprague Dawley rats (280 g, Charles River, UK) were randomly distributed in 5 groups 
(n=4 or n=3 for controls) and fasted over night (18 h) with free access to water at all times. The rats 
were orally dosed with a griseofulvin suspension in water and polymer, griseofulvin formulations 
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prepared above (11.8 mgKg
-1
) via oral gavage (2mL). Blood samples (approximately 100 µL) were 
collected using 300µL microvettes (Microvette
®
CB300, Vet Tech Solutions, UK) at various time 
points via tail vein venesection. After the first time point (1 h) food was given to the rats. Blood 
samples were centrifuged at 2000 rpm for 10 min and the plasma was frozen for further analysis. 
Griseofulvin was extracted from the plasma by diluting 100 µL plasma with 250 µL acetonitrile. 
The mixture was vortexed for 30s and then centrifuged at 3000 rpm for 10 min. The supernatant (50 
µL) was injected into a HPLC system consisting of a RP Zorbax ODS column 250 mm x 46 mm x 5 
µm  (Hichrom, UK) with the mobile phase flowing at 2 mLmin
-1
 (50:50 v/v acetonitrile:water). The 
resultant peak at 3 min was analysed at 260 nm (excitation) and 389 nm (emission) using a 
fluorescent detector (Varian LC, Varian UK). Griseofulvin present in the samples was determined 
from a standard calibration curve carried out previously with griseofulvin spiked blank plasma 
samples (1.9 µgmL
-1 – 10 µgmL-1), R2 = 0.992. The statistical significance of the results was 
assessed using two-way analysis on variance ANOVA and Dunnett multiple comparison t-test via 
SPSS 13.0 for Windows. 
3 Results 
3.1 Drug loaded polymeric self-assemblies 
 Ch5 and Dansyl10 formulations were able to improve the solubility of 3 hydrophobic drugs 
and the level and type of hydrophobic pendant groups had significant impact on maximum drug 
solubilisation (Fig 2). 10% mole modification improved drug aqueous solubility compared to 5% 
mole counterparts, which is consistent with the trend reported by others [29]. Fmoc pendant groups 
were less effective in solubilising the drugs compared to Ch5 and Dansyl10 which exhibited the 
highest drug encapsulation (Fig 2). With Ch5 and Dansyl10, increasing polymer concentrations from 
1mgmL
-1
 to 6 mgmL
-1
 increased drug encapsulation regardless of the drug. In contrast no consistent 
trend was observed with Fmoc and Dansyl5 polymers (data not shown). Optimum solubilisation was 
achieved with Ch5 and Dansyl10 polymers at 6mgmL
-1
 concentration and polymer weight ratios of 
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10:1 (Fig 2). Dansyl10 exhibited the highest improvement in drug aqueous solubility demonstrating 
145-fold for prednisolone, 224-fold for propofol and 557-fold for griseofulvin respectively (Table 
1). Unlike most of the reported self-assembled polymers which often demonstrated low drug 
loading (LC), typically between 5%  to less than 20% [13,30], these PAA based amphiphilic 
polymers have substantial higher LC especially with Dansyl10 demonstrating up to 530 % LC 
(Table 1). Dansyl10 exhibited the highest EE among the polymers ranging from 28% to 53%.   
As a whole, the size of drug loaded polymeric self-assemblies increased compared to the 
unloaded self-assemblies (Table 1), and is in agreement with previous reports [30]. For Ch5 and 
Dansyl10, encapsulation of propofol resulted in a significant increase in size (~600nm) while the rest 
of the formulations typically have hydrodynamic size of 300-400nm. An increase in polydispersity 
index (PDI) is observed in drug loaded Ch5 after drug encapsulation while this was not evident in 
Dansyl10.  It is possible that Dansyl10 are more efficient solubilisers than Ch5 and thus the drug 
loaded particles are less heterogeneous.  TEM images showed that all drug loaded nanoparticles 
were spherical in shape, however they were smaller than those obtained from PCS measurement 
(Fig 3B1-3).  This could be due to the fact that PCS measures the hydrodynamic radius of a particle 
that is generally slightly larger than the actual geometrical radius of a sphere due to solvation of the 
particle. 
3.2 In vitro drug release 
The in vitro drug release of the 3 drugs from the two best amphiphilic polymers, Ch5 and Dansyl10 
were assessed in PBS under sink condition (Fig. 4). Apart from griseofulvin, generally Ch5 resulted 
in rapid release where most drugs (between 50-60%) had been released in the first 7h while the 
release of drugs from Dansyl10 formulations were slower with only approximately 20% of the drugs 
being released after 7h. The release profile of Dansyl10 formulations seems to be independent of the 
encapsulated drug. It is possible that good compatibility between Dansyl10 and the 3 drugs resulted 
in a slower release of drug from the self-assemblies, which corresponds well with the high drug 
 10 
 
loading capacity [31]. For most formulations, 100% drug release was achieved between 3 to 4 days 
(data not shown). 
 
3.3 Formulation stability 
Fig 5 shows the amount of drug lost analysed by HPLC over a 4 week period. It was found that the 
freeze-dried propofol formulations following reconstitution did not contain any drug at week 0 
indicating the lost of drug in the freeze-drying process, perhaps due to the volatile nature of this 
drug. Therefore the stability of propofol formulations was subsequently determined using liquid 
formulations.  Over a 4 week period, Ch5, propofol liquid formulations experienced gradual drug 
lost from 0 to 30% while Dansyl10, propofol liquid formulation was able to retain up to 85% of the 
drug at the end of the 4 week period. This result is consistent with the hydrodynamic size data. The 
size of propofol encapsulated Ch5 self-assemblies reduced from 666nm to 239nm at the end of the 
study indicating drug lost while the Dansyl10, propofol formulation retained the same size at 677nm 
as in week 0 (Table 1). The initial drug lost (10-15%) at week 0 from both Ch5 and Dansyl10 freeze-
dried prednisolone and griseofulvin formulations was perhaps due to the freeze drying process (Fig 
5). Interestingly, Ch5 freeze-dried formulations were more stable than Dansyl10 formulations as no 
further notable loss was apparent over the 4 week however Dansyl10, griseofulvin formulation 
experienced significant drug (40%) lost at the end of the study together with an increase in 
aggregation size to 1µm. 
 
3.4 Haemocompatibility  
Fig 6A shows that apart from Dansyl5, all aromatic grafted PAA polymers were non-haemolytic 
(<10%) within the concentration range tested, which is similar to the PAA parent polymer. The 
deviation of Dansyl5 from this trend is not well understood. Unlike other alkyl chain grafted 
amphiphilic polymers, these aromatic grafted PAA showed better haemocompatibility [10]. It has 
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been reported that grafting of hydrophobic alkyl pendant groups tend to increase haemolytic activity 
due to the anchoring of pendant groups into the red cell (RBC) membrane [32]. Our result suggests 
the inability of aromatic groups to insert into the red blood cell membrane as readily as hydrocarbon 
chains. Ch5 polymers at higher concentrations precipitated when in contact with the suspension of 
RBC in PBS and hence we only tested the haemolytic effect up to 0.1mgmL
-1
, which showed no 
haemolytic activity (<0.5%).  The RBCs upon incubation with Dansyl10 at highest concentration 
have similar biconcave, spherical shape as RBC in PBS indicating that the polymer did not cause 
cell lysis or changed its morphology (Fig 6B). 
 
3.5 Cytotoxicity  
MTT assay was conducted using CaCo-2 cells to determine the polymer concentration required to 
kill 50% of the cells and the results are shown in Table 1. Higher IC50 value indicates the polymer is 
less cytotoxic. The unmodified PAA has an IC50 value of 23.3± 20.1µgmL
-1
.  Modification with the 
aromatic or cholesteryl moieties did not result in notable differences between the IC50 of the 
modified polymers and the unmodified PAA (Table 1). A slight increase in IC50 was observed when 
% of hydrophobic modification for Dansyl5 is increased to Dansyl10. It is known that primary 
amines are cytotoxic [33]. It is possible that the reduction of primary amines on the polymer 
backbone upon higher level of Dansyl modification leads to better biocompatibility.  
 
3.6 Intragastric administration of griseofulvin formulations in rats 
Griseofulvin in water and two polymer formulations were administered to rats via oral gavage. No 
gross acute toxicity was observed in all formulation and control groups. At all time points, the 
polymer, griseofulvin formulations have significantly higher plasma drug levels than griseofulvin in 
water (p<0.0001) indicating the ability of these polymers to improve the oral absorption of 
griseofulvin (Fig. 7). Ch5 has higher plasma drug concentration when compared to Dansyl10 at all 
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time points (p<0.001). The lower absorption observed in Dansyl10 formulation could be due to 
higher critical association concentration (CAC) for Dansyl10 (0.25mgmL
-1
) compared to Ch5 
(0.093mgmL
-1
) [18]. In addition, both polymers also showed different absorption profiles. For Ch5, 
the maximum plasma concentration was found at 4h time point while Dansyl10 formulation 
achieved highest plasma drug concentration at 1h. This suggests that griseofulvin absorption 
occurred in the small intestine for Ch5 while Dansyl10 occurred in the stomach.  
 
4 Discussion 
 In this work, we have synthesised four novel aromatic modified  PAAs (Fmoc5, Fmoc10, 
Dansyl5 and Dansyl10) and sterol modified  PAA (Ch5). Using three hydrophobic drugs with 




 (prednisolone) and 0.03mgmL
-1
 
(griseofulvin) respectively, we have shown that all modified PAAs described in this work were able 
to encapsulate these drugs within their hydrophobic core and increased the water solubility. Many 
studies on amphiphilic block copolymers have shown that increasing the hydrophobic monomer 
content would result in higher lipophilic content and thus causing stronger interaction with the drug 
molecules, leading to higher drug encapsulation [34]. This result is no exception to the trend where 
we observed that our novel aromatic modified  PAAs with 10% mole  modification significantly 
enhanced drug solubility when compared with their 5%mole counterparts.  
 Comparison among the aromatic grafted PAAs, reveals the poor solubilising capacity of 
Fmoc with low LC and EE compared to Dansyl. We have shown previously that Fmoc modified 
PAA polymers formed excimers at higher polymer concentrations [18]. The flat stereochemistry of 
aromatic structures allow - stacking and hence forming excimers, a known phenomenon 
supported by others [35]. This limits the expansion of the core to accommodate more drugs at 
higher concentrations (Fig 8a). The trend agrees well with smaller increase in the hydrodynamic 
size of the loaded self-assemblies compared to Dansyl formulations (Table 1).  In contrast, the 
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presence of the N,N-dimethylamino side chain in the Dansyl moiety gives rise to a 3D structure, 
that hinders any stacking interactions of the aromatic rings [18]. As a result this allows the self-
assemblies to enlarge its core to accommodate larger amount of drug molecules, which is in 
agreement with an increase of the hydrodynamic size when compared with their unloaded self-
assemblies and high LC and EE (Table 1) (Fig 8b).  
Interestingly, Dansyl10 self-assemblies seem to have universal drug solubilising capacity, 
demonstrating very low excipient to drug ratio across three drugs, i.e. 0.13 (propofol), 0.34 
(griseofulvin) and 0.19 (prednisolone). This is significantly lower than traditional drug solubilisers 
such as low molecular weight surfactants, cyclodextrins or co-solvents systems which typically 
have excipient to drug ratio ranging from 15:1 to as high at 1000:1 [10] In addition, these novel 
amphiphilic grafted PAA solubilisers also showed much higher LC (>100%) compared to most of 
the reported block amphiphilic polymers (<20%) [8,13,29] and other alkyl or aryl chain grafted 
amphiphilic polymers based on polyethylenimine [10] or chitosan [36]. To the best of our 
knowledge, preformed water-soluble polymer backbone grafted with aromatic pendant groups 
which exhibited high LC has not been previously reported. This may be due to better compatibility 
between the aromatic dansyl pendant groups and the cyclic/ aromatic drugs, although more work, 
i.e. solubility parameters, X-ray diffraction, FTIR data are required to confirm this hypothesis. 
Another possible explanation could be due to these Dansyl pendant groups acted as hydrotropic 
agents. Park and colleagues have published extensively on the use of N,N-diethylnicotinamide 
(DENA)  as hydrotropes to increase the solubility of poorly soluble drugs such as paclitaxel [37]. 
They also showed that block amphiphilic polymer consists of polyethylene glycol –b-poly(2-(4-
vinylbenzloxy)- N,N-diethylnicotinamide) (PEG-b-PCVBODENA) was able to enhance paclitaxel 
solubility significantly compared to plain PEG-b-poly(D,L-lactide) (PEG-b-PLA) [18]. The DENA 
group has similarities to the Dansyl pendant groups where both have aromatic structures with a side 
chain.  The authors also reported that DENA enhanced the stability of paclitaxel loaded PEG-b-
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PCVBODENA polymeric micelles. Freeze-dried prednisolone and liquid propofol Dansyl10 
formulations also exhibited reasonably good stability over one month period although it would 
appear that with Ch5, griseofulvin formulation was more stable than the Dansyl10 formulations. 
Although Ch5 did not significantly enhance drug solubility when compared with Dansyl10, 
overall it has superior drug loading capacity to other block amphiphilic polymers. It is expected that 
cholesteryl pendant group would solubilise prednisolone better due to ‘like-dissolves-like’ concept. 
However, this trend is not observed in our study. Instead, Ch5 increased propofol solubility by 78-
fold compared to prednisolone (32-fold) and griseofulvin (40-fold). This may be due to the core 
forming sterol moieties being rigid and hence restrict entry to larger drug molecules, prednisolone 
(Mw= 360gmol
-1
) and griseofulvin (Mw=353gmol
-1
) while they are able to accommodate smaller 
drug molecules like propofol (Mw=178gmol
-1
). Previously we showed that Ch5 core had highest 
microviscosity compared to cetyl or palmitoyl grafted PAA which may explain the phenomenon 
observed in this study [3]. 
Both Dansyl10 and Ch5 consistently achieved optimum drug to polymer initial feed ratios of 
10:1 at polymer concentration of 6mgmL
-1
. For example, at 5:1 drug to polymer initial feed ratio, 
Dansyl10 improved prednisolone solubility by 20-fold but was able to enhance the solubility of 
prednisolone by 147-fold at 10:1 ratio. For Dansyl10 and Ch5 increased initial drug feed ratios 
encouraged the uptake of drugs into the hydrophobic core resulting in lower EE which might be an 
issue if the drugs are expensive (Table 1) 
Liu and colleagues had shown that compatibility between drug and the hydrophobic 
segments forming the hydrophobic core of the block amphiphilic polymers will determine the drug 
solubilising capacity as well as the drug release profile [31]. They demonstrated that the release rate 
of ellipticine, a model hydrophobic drug from polymeric micelles was in the order of the 
compatibility between the hydrophobic segment and the drug where the better the compatibility, the 
lower the release rate [31]. This is similar to the trend observed where Dansyl10 exhibited higher LC 
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than Ch5 for all 3 drugs and slower release profile, presumable due to better compatibility as 
described by Liu and colleagues although more experimental data such as FTIR and X-ray 
diffraction are required to confirm this hypothesis   
It is understood that biocompatibility of a novel drug solubiliser is equally important as its 
solubilising capacity. Alkyl and acyl chains are known to anchor into bilayers of cell membranes 
creating pores or to form mixed micelles with phospholipid bilayers which will lead to an increase 
in haemolytic activity and cytotoxicity. In contrast, the presence of cyclic or branching groups 
decreased haemolytic activity [38]. Grafting of either Fmoc or Dansyl aromatic groups did not 
increase haemolytic activity compared to unmodified PAA. Similar to the cyclic structure, it is 
possible that the inflexible aromatic structure was not able to anchor into the bilayer as readily as 
alkyl chains. Interestingly, Fmoc5 appears to deviate from this trend and this is not well understood. 
The cytotoxicity assay also indicates the addition of aromatic or cholesteryl pendant groups did not 
enhance the cytotoxicity of PAA. 
To elucidate the ability of these PAA  amphiphilic polymers in delivering hydrophobic drug 
orally, griseofulvin was used as a model drug. According to Biopharmaceutics Classification 
System (BCS), griseofulvin is a class II drug which exhibits poor solubility but high permeability 
[39]. The rate determining step for griseofulvin is the dissolution process. Using similar dose as the 
clinical dose (11.8mgkg
-1
), we were able to demonstrate that both Dansyl10 and Ch5 formulations 
showed significantly higher plasma drug level compared to griseofulvin in water. This could be due 
to the rate determining step has been eliminated since griseofulvin encapsulated in the self-
assemblies would not require dissolution step before absorption. This was the mechanism proposed 
by Kano and colleagues when they reported the use of block amphiphilic polymer, poly[2-
methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate] (PMB) for enhancing the oral 
absorption of griseofulvin [40].  They compared extensively the griseofulvin pharmacokinetic data 
of a range of delivery systems such as niosomes, liposome, self-emulsifying drug delivery systems 
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and spray dried microparticles in rats using data published in the literature. They concluded that 
PMB have similar Cmax/Dose ratios with most of the formulations which range from 0.02 to 0.19. 
Interestingly our result showed a much higher Cmax/Dose ratios of 1.44 (Ch5) and 0.85 (Dansyl10). 
Although direct comparison is not applicable, however the high plasma drug concentrations 
achieved in both PAA formulations and the differences observed between these formulations 
perhaps indicate there are other contributing factors at play apart from solubilisation mechanism. 
Although Dansyl10 exhibits higher solubilisation, however the in vivo result demonstrates 
Ch5 formulation had significantly higher drug plasma concentrations at all time points with the 
maximum plasma drug concentration achieved at 4h. Since it is thought that oral drug absorption 
using self-assembled nanoparticles is much more complex and hence we cannot assume higher 
solubilisation implies better delivery. To date, there are limited in vivo studies on the use of 
amphiphilic polymers for improving bioavailability of hydrophobic drugs. Pierri and colleagues 
attempted to use Poly(lactide)-poly(ethylene glycol) micelles as oral carriers for griseofulvin but did 
not able to proceed to in vivo study due to the extremely poor drug loading capacity (4% w/w) [13].  
The trend we observed could be due to Ch5 has a much lower CAC (0.0093mgmL
-1
) compared to 
Dansyl10 (0.25mgmL
-1
) and hence it did not lose the hydrophobic payload upon dilution in the 
gastrointestinal tract [18]. Another possible explanation could be the polymer architecture affects 
the interaction between drug loaded self-assemblies with the gut enterocytes. In our previous work, 
we showed that quaternised palmitoyl modified PAAs were able to promote insulin uptake into 
cytoplasm of CaCo-2 cells via an active transport while non-quaternised palmitoyl modified PAA 
did not [17]. Therefore, further work is still required to elucidate the interaction between the drug 
loaded self-assemblies with the intestinal cells and subsequent absorption. In addition, the effect of 
food, the stomach acidity, the presence of bile salts and other physiological factors might affect the 






This study demonstrated for the first time  attachment of 10% mole aromatic pendant groups 
(Dansyl) to a preformed water soluble polymer backbone poly(allylamine) exhibited superior 
solubilising capacity for all three hydrophobic drugs compared to Fmoc PAA or cholesteryl grafted 
PAA. Its ability to expand its hydrophobic core and possibly better compatibility with the cyclic or 
aromatic drugs resulted in slower drug release profile and high drug loading capacity. The in vivo 
study also revealed that Ch5 and Dansyl10 were able to significantly improve the oral bioavailability 
of griseofulvin, a class II drug suggesting their potential as novel solubilisers for oral delivery.  
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